Praxis Precision Medicines Inc (PRAX)

$303.38 -1.62 (-0.53%)
Market Cap 8.19B
Revenue (ttm) 0.00
Net Income (ttm) -303.27M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 218,300
Avg Vol 490,846
Day's Range N/A - N/A
Shares Out 27.85M
Stochastic %K 38%
Beta 2.86
Analysts Strong Sell
Price Target $600.71

Company Profile

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Solidus to discover and develop antisense oligonucleotide. It also develops ulixacaltamide, a small molec...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 300 8460
Address:
99 High Street, 30th Floor, Boston, United States
Brianum2011
Brianum2011 Mar. 17 at 10:42 PM
$PRAX I’m a neurologist and holding this stock because I love their pipeline esp for ET and focal epilepsy
0 · Reply
De12
De12 Mar. 17 at 5:53 PM
$TENX Steve Cohen wants another $PRAX !!
0 · Reply
GfromTn
GfromTn Mar. 17 at 2:19 PM
$CRML I am not looking for 12.88 or even $20 like I told @Bigbas im looking for 67-73!!! If you’re not paying attention that’s on you I think even the bears know what the potential is here and that’s what scare them so badly I bet most will get out and try to reshort in 30-40 range but I don’t think it’s stopping there this time round I warned people about $PRAX when it was close to $100 and now it’s over $300 and will be around 4-500 this year keep listening to these folks who don’t make money I will keep listening to my due diligence
3 · Reply
AngusMacbeth
AngusMacbeth Mar. 17 at 1:55 PM
$PRAX Added a little at $305.
0 · Reply
De12
De12 Mar. 13 at 1:59 PM
$TENX Steve Cohen wants $200 like $PRAX!
0 · Reply
GfromTn
GfromTn Mar. 12 at 4:17 PM
$PRAX going to add a few more shares here anything under 3 is a gift to me but trade responsibly and know your risk tolerance
0 · Reply
Quantumup
Quantumup Mar. 11 at 1:09 PM
BTIG⬆️the PT on $RAPP to $53 from $47 and reiterated at a Buy rating. $XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities. Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with $490.5M in cash and equiv, funding operations into 2H29.
0 · Reply
De12
De12 Mar. 6 at 10:50 PM
$EDSA Steve Cohen and Ceo going to Destroy Shorts Together! look what he did at $PRAX!
1 · Reply
De12
De12 Mar. 6 at 10:11 PM
$EDSA $20, 30 $50? possible with only 8 Million Shares! Steve Cohen Loaded up! he wants another $PRAX
1 · Reply
De12
De12 Mar. 6 at 3:42 PM
$EDSA Steve Cohen loading More Shares! he wants another $PRAX
0 · Reply
Latest News on PRAX
Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Mar 6, 2026, 4:45 PM EST - 11 days ago

Praxis Precision Medicines, Inc. (PRAX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2026, 4:01 PM EST - 13 days ago

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Feb 20, 2026, 12:10 PM EST - 25 days ago

Praxis Precision Medicine Analysts Raise Their Forecasts After Q4 Results

Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript

Feb 19, 2026, 4:15 PM EST - 26 days ago

Praxis Precision Medicines, Inc. (PRAX) Q4 2025 Earnings Call Transcript

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Feb 19, 2026, 7:30 AM EST - 26 days ago

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

Feb 9, 2026, 4:01 PM EST - 5 weeks ago

Praxis Precision Medicines to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 19, 2026, and Participate in Upcoming Investor Conferences

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

Feb 2, 2026, 9:57 AM EST - 6 weeks ago

SEQSTER Announces Expanded Partnership with Praxis Precision Medicines to Accelerate Clinical Trials in CNS Disorders

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 7 weeks ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Jan 8, 2026, 4:45 PM EST - 2 months ago

Praxis Precision Medicines Further Positioned for Next-Phase Growth with Key Board and Executive Appointments

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Jan 6, 2026, 11:15 PM EST - 2 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $575 Million Public Offering

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Jan 6, 2026, 4:03 PM EST - 2 months ago

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Dec 29, 2025, 9:48 AM EST - 2 months ago

Praxis Precision Medicines To Rally More Than 213%? Here Are 8 Top Analyst Forecasts For Monday

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Dec 29, 2025, 8:00 AM EST - 2 months ago

Praxis Precision Medicines Announces the FDA Has Granted Breakthrough Therapy Designation for Ulixacaltamide HCl in Essential Tremor

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Dec 11, 2025, 8:00 AM EST - 3 months ago

Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Dec 9, 2025, 4:01 PM EST - 3 months ago

Praxis Precision Medicines Announces Alignment with FDA on Simplified and Accelerated Registrational Pathway for Elsunersen in Early Onset SCN2A Developmental and Epileptic Encephalopathy

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Dec 5, 2025, 1:10 PM EST - 3 months ago

Praxis' Epilepsy Drug Too Good To Continue, FDA Meeting Up Next

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Dec 4, 2025, 4:10 PM EST - 3 months ago

Praxis Precision Medicines Announces Positive Results from EMBOLD Study for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Dec 4, 2025, 4:01 PM EST - 3 months ago

Praxis Precision Medicines Announces Positive Pre-NDA Meeting with FDA for Ulixacaltamide in Essential Tremor

Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET

Nov 26, 2025, 3:57 PM EST - 3 months ago

Praxis: Moving To Strong Buy Based On Ulixacaltamide Success In Treating ET

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies Transcript

Nov 24, 2025, 8:23 PM EST - 4 months ago

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Program and Statistical Modeling Approaches in Clinical Studies Transcript

Praxis Precision Medicines, Inc. (PRAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 21, 2025, 8:33 PM EST - 4 months ago

Praxis Precision Medicines, Inc. (PRAX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Nov 20, 2025, 4:01 PM EST - 4 months ago

Praxis Precision Medicines to Participate in Upcoming Fireside Chat

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Nov 20, 2025, 1:55 PM EST - 4 months ago

Short Seller Alleges Praxis Precision's Potential $3 Billion Drug 'A House Of Cards'

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

Nov 3, 2025, 9:58 AM EST - 4 months ago

Biotech is back. Here's why these rallying stocks belong in your portfolio now.

ABBV ALNY AMGN BMY LLY MBX MDGL

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Oct 16, 2025, 11:45 PM EDT - 5 months ago

Praxis Precision Medicines, Inc. Announces Pricing of $525 Million Public Offering

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript

Oct 16, 2025, 8:56 PM EDT - 5 months ago

Praxis Precision Medicines, Inc. (PRAX) Discusses Essential3 Topline Results and Next Steps in Essential Tremor Program Transcript

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Oct 16, 2025, 2:14 PM EDT - 5 months ago

Praxis Precision's tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Oct 16, 2025, 12:02 PM EDT - 5 months ago

What's fueling PRAX stock's jaw-dropping 235% surge on Thursday?

Praxis Precision Medicines' movement disorder drug shows promise in trials

Oct 16, 2025, 7:09 AM EDT - 5 months ago

Praxis Precision Medicines' movement disorder drug shows promise in trials

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Sep 29, 2025, 7:00 AM EDT - 6 months ago

ReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate Update

Praxis Precision Medicines to Participate in September Investor Conferences

Sep 4, 2025, 4:01 PM EDT - 6 months ago

Praxis Precision Medicines to Participate in September Investor Conferences

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

Aug 25, 2025, 4:01 PM EDT - 7 months ago

Praxis Medicines to Present at 36th International Epilepsy Congress 2025 in Lisbon, Showcasing Latest RADIANT Study Data and Leading Precision Epilepsy Pipeline

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

Aug 14, 2025, 9:28 AM EDT - 7 months ago

PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Aug 5, 2025, 5:50 PM EDT - 8 months ago

Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm

Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 12:49 PM EDT - 8 months ago

Praxis Precision Medicines, Inc. (PRAX) Q2 2025 Earnings Call Transcript

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 8:30 AM EDT - 8 months ago

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Jul 17, 2025, 8:00 AM EDT - 8 months ago

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relutrigine for the Treatment of Seizures Associated with SCN2A and SCN8A Developmental and Epileptic Encephalopathies

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

May 7, 2025, 3:26 PM EDT - 11 months ago

Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 2, 2025, 8:30 AM EDT - 11 months ago

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Apr 8, 2025, 8:00 AM EDT - 1 year ago

Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Praxis Precision Medicines to Participate in Upcoming April Conferences

Apr 3, 2025, 5:00 PM EDT - 1 year ago

Praxis Precision Medicines to Participate in Upcoming April Conferences

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Mar 3, 2025, 11:03 PM EST - 1 year ago

Praxis: A High-Risk, High-Reward Epilepsy Play Post Ulixacaltamide (Rating Upgrade)

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Feb 28, 2025, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Provides Update on Essential3 and Corporate Update

Praxis Precision Medicines to Present at Two February Investor Conferences

Feb 3, 2025, 5:00 PM EST - 1 year ago

Praxis Precision Medicines to Present at Two February Investor Conferences

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Jan 12, 2025, 9:00 PM EST - 1 year ago

Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Dec 18, 2024, 8:00 AM EST - 1 year ago

Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome

Brianum2011
Brianum2011 Mar. 17 at 10:42 PM
$PRAX I’m a neurologist and holding this stock because I love their pipeline esp for ET and focal epilepsy
0 · Reply
De12
De12 Mar. 17 at 5:53 PM
$TENX Steve Cohen wants another $PRAX !!
0 · Reply
GfromTn
GfromTn Mar. 17 at 2:19 PM
$CRML I am not looking for 12.88 or even $20 like I told @Bigbas im looking for 67-73!!! If you’re not paying attention that’s on you I think even the bears know what the potential is here and that’s what scare them so badly I bet most will get out and try to reshort in 30-40 range but I don’t think it’s stopping there this time round I warned people about $PRAX when it was close to $100 and now it’s over $300 and will be around 4-500 this year keep listening to these folks who don’t make money I will keep listening to my due diligence
3 · Reply
AngusMacbeth
AngusMacbeth Mar. 17 at 1:55 PM
$PRAX Added a little at $305.
0 · Reply
De12
De12 Mar. 13 at 1:59 PM
$TENX Steve Cohen wants $200 like $PRAX!
0 · Reply
GfromTn
GfromTn Mar. 12 at 4:17 PM
$PRAX going to add a few more shares here anything under 3 is a gift to me but trade responsibly and know your risk tolerance
0 · Reply
Quantumup
Quantumup Mar. 11 at 1:09 PM
BTIG⬆️the PT on $RAPP to $53 from $47 and reiterated at a Buy rating. $XENE $PRAX $BHVN $JAZZ CNTA ALKS UCBJY BTIG said in its note—Rapport remains on track to initiate its Phase 3 FOS program in 2Q26 and continues advancing multiple indication expansion opportunities (PGTCS and bipolar mania) and lifecycle management (RAP-219 LAI) opportunities. Based on RAP-219's open-label Phase 2a FOS data — which showed RAP-219 reduced long episodes by 71% and clinical seizures by 78% — we see a potential best-in-disease profile for RAP-219 as an adjunctive therapy... We have added PGTC seizures into our RAP-219 market forecast based on mechanistic validation and de-risking Ph2a. Co ended 4Q25 with $490.5M in cash and equiv, funding operations into 2H29.
0 · Reply
De12
De12 Mar. 6 at 10:50 PM
$EDSA Steve Cohen and Ceo going to Destroy Shorts Together! look what he did at $PRAX!
1 · Reply
De12
De12 Mar. 6 at 10:11 PM
$EDSA $20, 30 $50? possible with only 8 Million Shares! Steve Cohen Loaded up! he wants another $PRAX
1 · Reply
De12
De12 Mar. 6 at 3:42 PM
$EDSA Steve Cohen loading More Shares! he wants another $PRAX
0 · Reply
R84877P
R84877P Mar. 5 at 10:53 PM
$PRAX As someone who has had this stock for 3 years, you will highly regret panic selling. Especially if it's projected to be over 1k by end of 2026. Just enjoy the ride.
1 · Reply
Quantumup
Quantumup Mar. 5 at 4:25 PM
H.C. Wainwright⬆️ $DRUG's PT to $145 , plus⬆️PoS for the absence epilepsy program to 60% and reiterated at a Buy after catching up w/ Bright Minds MGMT. LBPH - HLUBF / HLBBF UCBJY STOK - BIIB $JAZZ $PRAX Here's what H.C. Wainwright said: https://x.com/Quantumup1/status/2029593548509810731?s=20
0 · Reply
De12
De12 Feb. 27 at 9:26 PM
$TENX next $PRAX
0 · Reply
3_19
3_19 Feb. 27 at 3:38 PM
$PRAX Protecting 340 today Shorts
0 · Reply
TUNE477
TUNE477 Feb. 26 at 8:33 PM
$PRAX another fake out every time it goes above 340 it just can’t breakout it goes back down lol
0 · Reply
TUNE477
TUNE477 Feb. 26 at 4:56 PM
$PRAX this stock has too many fake outs
1 · Reply
TUNE477
TUNE477 Feb. 26 at 3:00 PM
$PRAX this thing can’t break that resistance it’s tried so many times
2 · Reply
R84877P
R84877P Feb. 25 at 5:16 PM
$PRAX $375 premarket. Closer and closer to $400 :)
2 · Reply
TUNE477
TUNE477 Feb. 24 at 11:09 PM
$IBRX could this be the next $PRAX
0 · Reply
Okadarlan
Okadarlan Feb. 24 at 10:16 PM
$PRAX less then half a million volume what a nice 🙂 stock, I added 3 x to short around 350 let's fcking go .
2 · Reply